The U.K. OTC market is, as the Brits would say, brilliant. For North American brand owners, it’s always on the list of attractive potential markets. Complex and unique, there are two “B”s that stand out — Boots and Brexit.
Theranos is facing its latest crisis following its withdrawal of its request for emergency clearance of a Zika-virus blood test after federal regulators found that the company didn’t include proper patient safeguards in a study of the new test, The Wall Street Journal reported Tuesday, citing people familiar with the matter. "Theranos founder Elizabeth Holmes announced Aug. 1 a new blood-testing device called miniLab that she said was designed for use outside a clinical laboratory and could run accurate tests from a few drops of blood," The Journal wrote. "But during an inspection by the FDA earlier this month, regulators concluded that Theranos had collected some data supporting the accuracy of the Zika test without implementing a patient-safety protocol approved by an institutional review board." (The Wall Street Journal)
A leading beverage brand in Europe and the Middle East is launching a no sugar added line of its exotic juice beverages in the United States.
The U.S. Food and Drug Administration has approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases.
This weekend's LSU-Wisconsin game at Lambeau Field marks the first major sports sponsorship for the 80-year-old brand, as part of a multi-year partnership with the Green Bay Packers.
Members of participating plans will be able to receive 90-day supplies of their diabetes maintenance meds from more than 10,000 pharmacies – including Walgreens and at more than 1,200 independent retail pharmacies.
Floating has seen exponential growth within the last few years and is one of the fastest growing niche industries in the country, the San Francisco Salt Company reported.
Consumers aren’t ready to let go of print coupons.
Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R&D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the formulary, The National Law Review suggested. (The National Law Review)
Jeff Jones, executive vice president, chief marketing officer at Target, is leaving the company.